La apolipoproteína -B como indicador bioquímico en la prevención del infarto del miocardio: estudio preliminar en Cuba

López Ruíz, Justo; Illnait Ferrer, José; Rojas Castañeda, Enis.
Rev. cuba. med ; 24(10): 1079-87, oct. 1985. ilus, tab
Artículo en Español | CUMED | ID: cum-2683

Documentos relacionados

  1. APOB and CCL17 as mediators in the protective effect of SGLT2 inhibition against myocardial infarction: Insights from proteome-wide mendelian randomization.
  2. The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study.
  3. Targeting the vivid facets of apolipoproteins as a cardiovascular risk factor in rheumatoid arthritis.
  4. Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment.
  5. Developing Electron Microscopy Tools for Profiling Plasma Lipoproteins Using Methyl Cellulose Embedment, Machine Learning and Immunodetection of Apolipoprotein B and Apolipoprotein(a).
  6. Comparative assessment of LDL-C and VLDL-C estimation in familial combined hyperlipidemia using Sampson's, Martin's and Friedewald's equations.
  7. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
  8. FAMILIAL COMBINED HYPERLIPIDEMIA: CURRENT KNOWLEDGE, PERSPECTIVES, AND CONTROVERSIES.
  9. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
  10. LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study.